Read by QxMD icon Read

NEPC clinical trials

Murali Gururajan, Karen A Cavassani, Margarit Sievert, Peng Duan, Jake Lichterman, Jen-Ming Huang, Bethany Smith, Sungyong You, Srinivas Nandana, Gina Chia-Yi Chu, Sheldon Mink, Sajni Josson, Chunyan Liu, Matteo Morello, Lawrence W M Jones, Jayoung Kim, Michael R Freeman, Neil Bhowmick, Haiyen E Zhau, Leland W K Chung, Edwin M Posadas
FYN is a SRC family kinase (SFK) that has been shown to be up-regulated in human prostate cancer (PCa) tissues and cell lines. In this study, we observed that FYN is strongly up-regulated in human neuroendocrine PCa (NEPC) tissues and xenografts, as well as cells derived from a NEPC transgenic mouse model. In silico analysis of FYN expression in prostate cancer cell line databases revealed an association with the expression of neuroendocrine (NE) markers such as CHGA, CD44, CD56, and SYP. The loss of FYN abrogated the invasion of PC3 and ARCaPM cells in response to MET receptor ligand HGF...
December 29, 2015: Oncotarget
A Kretschmer, C Wittekind, C G Stief, C Gratzke
BACKGROUND: Neuroendocrine carcinoma of the prostate (NEPC) is a rare, androgen-independent variant of prostate cancer with increasing incidence of over the past few years. It commonly progresses rapidly and is associated with a poor prognosis. Based on a different tumor biology compared to adenocarcinomas of the prostate, standard therapeutic approaches for prostate cancer are ineffective. To date, no specific treatment for NEPC exists. OBJECTIVES: The purpose of this work is to provide an overview of current histopathologic characteristics, histomorphologic classifications, and current as well as future treatment options for NEPC...
December 2015: Der Urologe. Ausg. A
Matteo Santoni, Alessandro Conti, Luciano Burattini, Rossana Berardi, Marina Scarpelli, Liang Cheng, Antonio Lopez-Beltran, Stefano Cascinu, Rodolfo Montironi
Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that commonly arises in later stages of castration resistant prostate cancer (CRPC) The detection of NEPC has clinical implications as these patients are often treated with platinum chemotherapy rather than with androgen receptor targeted therapies. The poor molecular characterization of NEPC accounts in part for the lack of disease specific therapeutics. Several mechanisms are involved in NE differentiation, including inflammation and autophagy, and may actually represent future therapeutic targets for advanced NEPC patients...
December 2014: Biochimica et Biophysica Acta
Hans Timmerman, Oliver Wilder-Smith, Chris van Weel, André Wolff, Kris Vissers
BACKGROUND: The presence of nerve damage plays a key role in the development and prognosis of chronic pain states. Assessment of the presence and severity of a neuropathic pain component (NePC) is key in diagnosing chronic pain patients. Low back pain (LBP) and neck and shoulder pain (NSP) are highly prevalent and clinically important medical and societal problems in which a NePC is frequently present. The more severe the NePC, the worse the course of the pain, its prognosis and the results of treatment...
2014: BMC Neurology
P Sargos, L Ferretti, M Gross-Goupil, M Orre, F Cornelis, B Henriques de Figueiredo, N Houédé, C Merino, G Roubaud, B Dallaudiére, P Richaud, A Fléchon
OBJECTIVES: Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well as therapeutic approach makes the management of those tumors a clinical challenge. This literature review aims to summarize available data on the characterization and management of patients with prostate cancer with a neuroendocrine element. We try to identify major controversies and uncertainties in order to understand all aspects of this particular entity...
September 2014: Prostate Cancer and Prostatic Diseases
Himisha Beltran, David S Rickman, Kyung Park, Sung Suk Chae, Andrea Sboner, Theresa Y MacDonald, Yuwei Wang, Karen L Sheikh, Stéphane Terry, Scott T Tagawa, Rajiv Dhir, Joel B Nelson, Alexandre de la Taille, Yves Allory, Mark B Gerstein, Sven Perner, Kenneth J Pienta, Arul M Chinnaiyan, Yuzhuo Wang, Colin C Collins, Martin E Gleave, Francesca Demichelis, David M Nanus, Mark A Rubin
UNLABELLED: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that most commonly evolves from preexisting prostate adenocarcinoma (PCA). Using Next Generation RNA-sequencing and oligonucleotide arrays, we profiled 7 NEPC, 30 PCA, and 5 benign prostate tissue (BEN), and validated findings on tumors from a large cohort of patients (37 NEPC, 169 PCA, 22 BEN) using IHC and FISH. We discovered significant overexpression and gene amplification of AURKA and MYCN in 40% of NEPC and 5% of PCA, respectively, and evidence that that they cooperate to induce a neuroendocrine phenotype in prostate cells...
November 2011: Cancer Discovery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"